First Patient Dosed in Phase II Clinical Trial for BioInvent's Cardiovascular Drug, BI-204
Trial start triggers US$ 15 million milestone from Genentech
BioInvent International AB announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome.
The Phase II study is a multicenter, randomized, double-blind, placebo-controlled study of BI-204, delivered intravenously to patients on standard-of-care therapy for stable atherosclerotic cardiovascular disease. The trial will enrol 120 patients at approximately 20 centres in the United States and Canada. It is designed to demonstrate a reduction in plaque inflammation following treatment as quantified by FDG-PET imaging (18F 2‑deoxyglucose positron emission tomography).
The antibody is being developed in collaboration with Genentech, a member of the Roche Group. BioInvent will receive a milestone payment of US$ 15 million from Genentech upon dosing of the first patient.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

Brain tissue from a petri dish
Thermo Fisher Scientific and George Mason University Partner in Protein Biomarker Research Project - Collaboration Aims to Accelerate Verification and Validation of Protein Biomarkers for Earlier Disease Diagnosis and Therapeutic Efficacy

Touchable corona viruses - Research group prints the first biologically correct 3D model of the SARS-CoV-2 virus

Drug reduces transplant and mortality rates significantly in patients with hepatitis C
BioOutsource Opens New Facility in Glasgow - Double’s the Company’s Capacity for Biologics Contract Testing and Biosimilar Characterisation
The Gene Center at Ludwig-Maximilians-Universität München and ExpreS2ion Biotechnologies Enter a Licensing Agreement

The 2024 Balzan Prizes Focus on Sustainable Progress - From Law to the History of Science, and from the Biology of Ageing to Innovative Materials: 750,000 Swiss Francs will be awarded to each of the four winners of the Balzan Prizes
Clavis Pharma expands Phase III CLAVELA study in patients with acute myeloid leukaemia (AML)
50-year search for calcium channel ends

BASF to invest USD 33 million in R&D facilities in Research Triangle Park - Focus on plant biotechnology and crop protection research
Shock_(medical)
